Conatus Pharmaceuticals Inc. (CNAT)

[Theo]

From the March earnings CC:

"Cash, cash equivalents and marketable securities were $74.9 million at December 31, 2017 compared with $77 million at December 31, 2016 and a projected year end 2018 balance of between $35 million and $40 million.

We believe our current financial resources together with the anticipated reimbursements for 50% of the cost for the four ongoing clinical trials without including any potential milestone payments under the Novartis agreement are sufficient to maintain operations through the topline results from all four Phase 2b clinical trials by the end of 2019, as well as to fundamentally initial pipeline expansion activities."

IF they get a milestone payment from Novartis (a percentage of the confirmed $650 million set aside for just that), then of course it only goes higher.